India · Delayed Price · Currency is INR NATCO Pharma Statistics
Total Valuation
NATCO Pharma has a market cap or net worth of INR 155.56 billion. The enterprise value is 141.41 billion.
| Market Cap | 155.56B |
| Enterprise Value | 141.41B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | Aug 20, 2026 |
Share Statistics
| Current Share Class | 196.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 26.77% |
| Owned by Institutions (%) | 10.44% |
| Float | 83.82M |
Valuation Ratios
The trailing PE ratio is 12.42 and the forward PE ratio is 19.96.
| PE Ratio | 12.42 |
| Forward PE | 19.96 |
| PS Ratio | 4.46 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | 11.27 |
| P/OCF Ratio | 8.80 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.78, with an EV/FCF ratio of 10.25.
| EV / Earnings | 12.36 |
| EV / Sales | 4.06 |
| EV / EBITDA | 11.78 |
| EV / EBIT | 14.33 |
| EV / FCF | 10.25 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.01 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.67 |
| Debt / FCF | 0.52 |
| Interest Coverage | 18.41 |
Financial Efficiency
Return on equity (ROE) is 16.85% and return on invested capital (ROIC) is 10.16%.
| Return on Equity (ROE) | 16.85% |
| Return on Assets (ROA) | 7.98% |
| Return on Invested Capital (ROIC) | 10.16% |
| Return on Capital Employed (ROCE) | 13.40% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 7.86M |
| Profits Per Employee | 2.58M |
| Employee Count | 4,433 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.80 |
Taxes
In the past 12 months, NATCO Pharma has paid 907.00 million in taxes.
| Income Tax | 907.00M |
| Effective Tax Rate | 7.34% |
Stock Price Statistics
The stock price has decreased by -3.87% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -3.87% |
| 50-Day Moving Average | 826.98 |
| 200-Day Moving Average | 930.81 |
| Relative Strength Index (RSI) | 42.23 |
| Average Volume (20 Days) | 36,077 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NATCO Pharma had revenue of INR 34.85 billion and earned 11.44 billion in profits. Earnings per share was 63.89.
| Revenue | 34.85B |
| Gross Profit | 28.80B |
| Operating Income | 8.56B |
| Pretax Income | 12.35B |
| Net Income | 11.44B |
| EBITDA | 10.70B |
| EBIT | 8.56B |
| Earnings Per Share (EPS) | 63.89 |
Balance Sheet
The company has 21.29 billion in cash and 7.14 billion in debt, with a net cash position of 14.15 billion.
| Cash & Cash Equivalents | 21.29B |
| Total Debt | 7.14B |
| Net Cash | 14.15B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 92.21B |
| Book Value Per Share | 514.92 |
| Working Capital | 33.71B |
Cash Flow
In the last 12 months, operating cash flow was 17.68 billion and capital expenditures -3.88 billion, giving a free cash flow of 13.80 billion.
| Operating Cash Flow | 17.68B |
| Capital Expenditures | -3.88B |
| Depreciation & Amortization | 2.14B |
| Net Borrowing | 4.24B |
| Free Cash Flow | 13.80B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.64%, with operating and profit margins of 24.56% and 32.84%.
| Gross Margin | 82.64% |
| Operating Margin | 24.56% |
| Pretax Margin | 35.45% |
| Profit Margin | 32.84% |
| EBITDA Margin | 30.70% |
| EBIT Margin | 24.56% |
| FCF Margin | 33.81% |
Dividends & Yields
This stock pays an annual dividend of 4.50, which amounts to a dividend yield of 0.57%.
| Dividend Per Share | 4.50 |
| Dividend Yield | 0.57% |
| Dividend Growth (YoY) | -10.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.04% |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.57% |
| Earnings Yield | 8.05% |
| FCF Yield | 8.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NATCO Pharma is 1,004.44, which is 26.61% higher than the current price. The consensus rating is "Hold".
| Price Target | 1,004.44 |
| Price Target Difference | 26.61% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 2.02% |
| EPS Growth Forecast (3Y) | -7.77% |
Stock Splits
The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Nov 26, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |